Envista (NYSE:NVST) Q4 2025 Earnings call February 05, 2026 05:00 PM ET Company ParticipantsElizabeth Anderson - Senior Managing DirectorEric Hammes - CFOJim Gustafson - VP of Investor RelationsJonathan Block - Managing DirectorKevin Caliendo - Healthcare Equity ResearchLilly Quezada - Senior Branch ManagerPaul Keel - CEOConference Call ParticipantsBrandon Vazquez - Research AnalystJeffrey Johnson - Senior Research AnalystSteven Valiquette - Managing Director and Senior Equity Research AnalystNone - Analyst ...

Financial Performance - Q3 FY2025 - Revenue reached $1.74 billion, exceeding guidance by over $60 million[9] - Reported revenue growth was +10.1%[7, 11] - Core revenue growth was +6.1%[7, 16] - EPS was $1.37, a +4% year-over-year increase[7, 9] - Operating margin was 25.1%[7, 9] FY2025 Outlook - Core growth outlook raised to 4.5%[9, 14] - Revenue guidance increased by $150 million at the midpoint[9] - Net Revenue guidance is $6.91 to $6.93 billion[34] - EPS guidance is $5.56 to $5.59[34] Segment Performance - Q3 FY2025 - LDG (Life Sciences and Diagnostics Group) core growth was +14%[18] - ACG (Agilent CrossLab Group) core growth was +5%[18] - AMG (Agilent Molecular Spectroscopy Group) core growth was +7%[18] Revenue Breakdown - Americas accounted for 39% of Agilent's revenue[23] - Europe accounted for 28% of Agilent's revenue[23] - Asia-Pacific accounted for 33% of Agilent's revenue[23]